Having questioned the company, here are my two cents regarding capacity:
- The Myriad, Symphony and Enivo products, which will be the significant future growth drivers, use fewer sheep stomachs per unit than Ovitex.
- Aroa will distribute Myriad, Symphony and Enivo itself rather than through a partner like TELA Bio, meaning they retain all the revenues.
- New Zealand has over 20 million sheep, and Aroa said they use less than 2% of that yearly.
- The $100 million revenue capacity figure is old. It was announced before the recent better-than-expected traction of the products Aroa sells directly, so I suspect it's higher now. Regardless, given the above, future capacity per million revenue should be much cheaper than in the past.
Having questioned the company, here are my two cents regarding...
Add ARX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
62.5¢ |
Change
-0.015(2.34%) |
Mkt cap ! $215.1M | |||
| Open | High | Low | Value | Volume |
| 64.5¢ | 64.5¢ | 62.0¢ | $47.64K | 76.21K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1699 | 61.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 62.5¢ | 309 | 1 |
View Market Depth
| Last trade - 16.10pm 14/06/2024 (20 minute delay) ? |
|
|||||
|
Last
62.0¢ |
Change
-0.015 ( 1.59 %) |
||||
| Open | High | Low | Volume | ||
| 63.0¢ | 63.0¢ | 62.0¢ | 33827 | ||
| Last updated 15.14pm 14/06/2024 ? | |||||
| ARX (ASX) Chart |